GLP1R and metabolic dysfunction-associated steatotic liver disease: A possible beneficial hepatic effect has been demonstrated with the use of GLP1 receptor agonists (GLP1-RA) and liraglutide has been the most studied in nonalcoholic fatty liver disease (NAFLD).